5/27/2022  5:38:32 PM Chg. +0.080 Volume Bid5/27/2022 Ask5/27/2022 Market Capitalization Dividend Y. P/E Ratio
7.980EUR +1.01% 2,023
Turnover: 15,698.920
-Bid Size: - -Ask Size: - 155.95 mill.EUR 0.00% -

Business description

BRAIN AG is one of Europe’s technological leaders in the field of industrial, or so-called white, biotechnology, the core discipline of the bioeconomy. Using proprietary technology platforms, the company identifies as yet untapped highly performant enzymes, microbial producer organisms or natural substances from complex biological systems in order to transform them into industrially or bioeconomically viable processes. Innovative solutions and products developed from this “toolbox of nature” are already successfully in use in the chemical industry as well as in the cosmetics and foodstuffs industry. BRAIN’s business model is based on two divisions: “BioScience“ and “BioIndustrial”. The “BioScience“ division includes the company’s collaboration business with selected, globally positioned industrial partners, which is usually concluded on an exclusive basis and which has been successfully built and continuously expanded by the company for more than 20 years. The second division, “BioIndustrial”, deals with the development and marketing of BRAIN’s proprietary products and active product components.

Management board & Supervisory board

Adriaan Moelker
Management board
Lukas Linnig
Supervisory board
Dr. Georg Kellinghusen, Dr. Anna C. Eichhorn, Dr. Michael Majerus, Prof. Dr. Bernhard Hauer, Prof. Dr.-Ing. Wiltrud Treffenfeldt, Stephen Catling

Company data

Name: BRAIN Biotech AG
Address: Darmstädter Straße 34-36,D-64673 Zwingenberg
Phone: +49-6251-9331-0
Fax: +49-6251-9331-11
E-mail: public@brain-biotech.de
Internet: www.brain-biotech.de
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 9/30
Free Float: 47.30%
IPO date: 2/9/2016

Investor relations

Name: Michael Schneiders
IR phone: +49-6251-9331-86
IR Fax: -
IR e-mail: ir@brain-biotech.de

Company calendar

CW 23 | 5/30/2022 Interim Report 2nd Quarter/6 Months
CW 36 | 8/29/2022 Interim Report 3rd Quarter/9 Months

Main Shareholders

MP Beteiligungs GmbH
Gründer und Management
DAH Beteiligungs GmbH
Lloyd Fonds